Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules

Bibliography

• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• NCCN Practice Guidelines in Oncology (v.1.2010): Colon cancer Available from: http://www.nccn.org [Last accessed 22 July 2010]
   Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE II, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-50
   PubMed Web of Science ®Google Scholar
• FDA Approval for Bevacizumab. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab [Last accessed 23 July 2010]
   Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-43
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines: renal cell carcinoma Available from: http://www.nccn.org [Last accessed 23 July 2010]
   Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Schwander B, Escudier BJ, Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. J Clin Oncol (Meeting Abstracts) 2010;28:4612
   Google Scholar
• NCT00720941: Study VEG108844, a Study of Pazopanib Versus Sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma Available from: http://www.clinicaltrials.gov [Accessed 22 December 2009
   Google Scholar
• NCT00631371: Phase 3b, Randomized, Open-Label Study of bevacizumab + temsirolimus ) vs bevacizumab + interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma. Available from: http://www.clinicaltrials.gov [Last accessed 29 March 2010]
   Google Scholar
• NCT00378703: The BeST Trial: a randomized phase II study of VEGF, RAF Kinase, and mTOR combination rargeted rherapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma [BeST] Available from: http://www.clinicaltrials.gov [Accessed 22 December 2009]
   Google Scholar
• NCT00719264: a randomized, open-label, multi-center Phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney. Available from: http://www.clinicaltrials.gov [Accessed 22 December 2009]
   Google Scholar
• Escudier BJ, Negrier S, Gravis G, Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol (Meeting Abstracts) 2010;28:4516
   Google Scholar
• Burstein HJ, Chen Y-H, Parker LM, VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008;14:7871-7
   PubMed Web of Science ®Google Scholar
• Schultheis AM, Lurje G, Rhodes KE, Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554-63
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8
   PubMed Web of Science ®Google Scholar
• Gordan JD, Lal P, Dondeti VR, HIF-[alpha] Effects on c-Myc distinguish two subtypes of sporadic vhl-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46
   PubMed Web of Science ®Google Scholar
• Brannon AR, Reddy A, Seiler M, Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63
   PubMedGoogle Scholar
• Escudier BJ, Ravaud A, Negrier S, Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol (Meeting Abstracts) 2008;26:5025
   Google Scholar
• Choueiri TK, Xie W, Kollmannsberger CK, The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration. J Clin Oncol (Meeting Abstracts) 2010;28:4524
   Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9
   PubMed Web of Science ®Google Scholar
• Dial E, Duh M, Fournier A, Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): a retrospective claims database analysis. J Clin Oncol (Meeting Abstracts) 2009;27:5112
   Google Scholar
• Bukowski RM, Kabbinavar FF, Figlin RA, Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-41
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34
   PubMed Web of Science ®Google Scholar
• FDA advisory committee recommends against bevacizumab for metastatic breast cancer Available from: http://www.cancer.gov/ncicancerbulletin/072710/page2 [Last accessed 28 July 2010]
   Google Scholar